Ctcbio Inc. (060590.KQ) Stock

060590.KQ logo

Ctcbio Inc.

060590.KQSouth Korea
Healthcare

Company profile

Ctcbio reported revenue of 123.77 billion KRW for fiscal year 2025, down 14.3% from fiscal year 2024. Its largest business segment, Animal and Human Medicine Sale, brought in 83% of segment revenue in fiscal year 2024; South Korea was the largest region with 99%. Our analysis of its filings shows revenue shrinking from 137.88 billion KRW in fiscal year 2023 to 123.77 billion KRW in fiscal year 2025, 5.3% a year on average. Ctcbio reports about 226 full-time employees.

What stands out

  • It returned to a profit in fiscal year 2025, 3.24 billion KRW, after 2 years of net losses (5.22 billion KRW in fiscal year 2024).

Figures from company filings; latest fiscal year ended December 31, 2025.

About Ctcbio Inc.

CTCBIO Inc. provides various pharmaceutical products in South Korea and internationally. The company offers animal and human pharmaceuticals; feed additives and ingredients; and functional food products. It also provides cardiovascular, gastrointestinal, osteoporosis, antibiotic, smoking cessation, antifungal and antiviral, antiepileptic, allergic rhinitis, dermatology and genito-urinory, allergic rhinitis and antihistamine, neuropsychiarty, intestinal disorders, X-ray, diabetes, anti-inflammatory and arthritis, and harmones, as well as CTC covid-19 IgM/IgG combo test, a quick antibody test kit on covid-19. In addition, the company offers coating base/plasticizer/pore former, diluting agents, bonding agents, disintegrating agents, lubricants, solubilizer/biopharma, topicals, APIs, and food/health functional foods, as well as animal drugs, physiological activators, functional enhancers, and disinfectants. CTCBIO Inc. was founded in 1993 and is headquartered in Hwaseong-si, South Korea.

Largest shareholders

  • Bionote, Inc.23.04%
  • Pharmaresearch Bio Co., Ltd.10.61%
  • Young-Sik Cho8.7 %8.70%
  • Ctcbio Inc.1.13%
  • Min-Ku Lee0.000004 %0.00%

Share of the company, as of September 25, 2026

Leadership

  • Sun Cho Chang — CEO & Executive Director, 62
  • SinGyu Kim — CEO & Executive Director, 61
  • Ho-Yeon Cho — President, 67
  • Seong-Rin Kim — President, 67
  • Keumho Lee — Executive Director, 52

How much revenue does Ctcbio make?

Ctcbio reported 123.77 billion KRW in revenue for fiscal year 2025, down 14.3% from 144.41 billion KRW in fiscal year 2024.

What is Ctcbio's largest business segment?

Animal and Human Medicine Sale, with 127.63 billion KRW or 83% of segment revenue in fiscal year 2024. Next: Hay Sale (16%) and Health Functional Food Sales (1%).

Where does Ctcbio make most of its revenue?

South Korea: 99% of revenue by region in fiscal year 2024, followed by Overseas (1%).

What companies are similar to Ctcbio?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Sinil Pharmaceutical Co., Ltd. (012790.KQ), Daehan Nupharm Co.,Ltd. (054670.KQ), PharmGen Science, Inc. (004720.KS), Ildong Holdings Co., Ltd. (000230.KS).

Has Ctcbio made a profit in recent years?

Net income by fiscal year: FY2021, a loss of 7.32 billion KRW; FY2022, 4.70 billion KRW; FY2023, a loss of 15.59 billion KRW; FY2024, a loss of 5.22 billion KRW; FY2025, 3.24 billion KRW. It reported a net loss in 3 of these 5 years.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees226
HeadquartersHwaseong-si, South Korea
ExchangeKOSDAQ
TimezoneAsia/Seoul (KST)

Contact & Links

Address
Tower A, 901, Hwaseong-si
Phone
82 1 661 8800
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Ctcbio Inc. (060590.KQ)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/060590.KQ

LinkedInLinkedInXXYouTubeYouTube